Blood Pressure Management and Dementia Risk — A Research Summary

Hypertension in midlife (40s-60s) is one of the largest modifiable risk factors for both Alzheimer's disease and vascular dementia. The Lancet 2020 Commission estimated hypertension accounts for approximately 2% of global dementia burden. Multiple large cohort studies confirm a 50-100% elevated dementia risk with sustained midlife hypertension.

The landmark SPRINT MIND RCT (2019, JAMA, 9,361 adults with hypertension, mean follow-up 3.3 years) demonstrated that intensive blood pressure control (systolic target below 120 mmHg) significantly reduced the incidence of mild cognitive impairment compared to standard control (below 140 mmHg). This is one of the most important RCTs in dementia prevention, demonstrating that treating a risk factor reduces downstream cognitive impairment.

White matter lesions — small areas of damaged brain tissue visible on MRI — are the mediating mechanism. Hypertension damages cerebral small blood vessels, producing these lesions in frontal and subcortical regions. Greater lesion burden correlates with processing speed decline and executive function impairment.

High blood pressure directly damages the small blood vessels (arterioles) supplying the brain's white matter. This produces lacunar infarcts and white matter hyperintensities — accumulated damage that impairs neural transmission and connectivity between brain regions. Reducing blood pressure preserves these vessels, reducing the rate of white matter damage.

Blood pressure also influences amyloid clearance: the glymphatic system depends on pulsatile arterial flow — the gentle pressure waves from a beating heart — to drive cerebrospinal fluid through the brain. Hypertension disrupts these pressure waves, potentially impairing amyloid clearance.

The SPRINT MIND target was systolic below 120 mmHg. Standard clinical guidelines have moved toward this more intensive target for cardiovascular risk reduction. Achieving and sustaining this target, whether through lifestyle changes or medication, is what drives cognitive benefit.

• Target systolic BP: below 130 mmHg (ideally below 120 per SPRINT MIND)
• Lifestyle: reduce sodium, increase potassium (fruits/vegetables), reduce alcohol, exercise, lose weight if overweight
• Medication: if lifestyle insufficient, antihypertensive medication is evidence-based and does not impair cognitive function at therapeutic doses
• Monitor: home blood pressure monitoring improves control — single clinic readings may miss masked hypertension

People with midlife hypertension (40s-60s) show the largest cognitive protective benefit from treatment — this is when hypertension does the most damage to white matter. People with APOE4 and hypertension may have compounded risk reduction from treatment. People with existing white matter lesions who lower BP have demonstrated slower lesion progression.

Know your number. Many people with hypertension are unaware of it — regular monitoring is the first step. DASH diet, sodium reduction below 2.3g/day, regular aerobic exercise, and alcohol reduction are the lifestyle foundations. If lifestyle changes are insufficient to achieve target, antihypertensive medication is highly effective and protects cognitive as well as cardiovascular health.